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Abstract
Purpose: In animal studies intravitreal injection of tetrodotoxin (TTX) results in mfERG waveform
changes similar to those observed in glaucoma. As TTX blocks amacrine as well as ganglion cells, there is
still a question regarding the underlying cell population responsible for these changes in waveform. In an
attempt to assess the contribution of the amacrine cells to these changes, a mfERG was obtained from
patients with Parkinson’s disease as some amacrine cells are mediated by dopamine, a substance lacking in
Parkinson’s. Methods: Eight patients with early Parkinson’s disease underwent ophthalmologic examina-
tion, testing of contrast sensitivity and electrophysiological examination according to ISCEV standard at
least 12 h following their last medication with Dopamine. A slow stimulation mfERG was obtained with a
stimulus base interval of 53.3 ms and with a stimulus base interval of 106.6 ms. During MF-ERG
recordings 103 hexagons stimulated the central 50 deg of the retina simultaneously and independently (m-
sequence 213, Lmax: 200 cd/m
2, 100% contrast). Results: Contrast sensitivity and ISCEV standard elec-
trophysiological testing was unremarkable. When the mfERG was analyzed, only four patients had an
adequate signal-to-noise ratio to allow further data analysis – one of whom was diagnosed with a multi
system atrophy in retrospect. The ﬁrst order response component was analyzed at a ﬁlter setting of 10–
300 Hz and at 100–300 Hz (OPs) and compared to mfERGs of a control group. On average, in patients, the
amplitude of N1P1 was slightly lower in the central and nasal response averages. When the three OPs at a
latency of 72–89 ms were analyzed in the 53.3 ms base interval recording, the most marked difference in
amplitude was observed in the superior nasal response average of the ﬁrst OP. Here a mean amplitude of
1.3 nV/deg2 in patients compared to a mean amplitude of 1.9 nV/deg2 in the control group (P: 0.08).
Discussion: In contrast to our previous ﬁndings in NTG, there was a consistent presence of three OPs.
Under the stimulus conditions applied, we did not ﬁnd an inﬂuence of dopaminergic amacrine cells on the
mfERG in our patients with moderate stages of Parkinsion’s. The difﬁculties in obtaining an adequate
signal-to noise ratio due to e.g. muscle artifacts even in Parkinson patients of moderate disease stages
render a success of mfERG recording in patients with more advanced stages unlikely. The question of the
inﬂuence of dopaminergic amacrine cells on the mfERG could possibly be addressed using MPDT in
animal research.
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Introduction
The multifocal electroretinogram (mfERG)
allows topographic mapping of retinal function.
It has been applied to analyze the function of
different retinal layers such as the outer [1–5] or
inner [6] retina.
Most research applying the mfERG to test in-
ner retinal function has been conducted in glau-
coma, a disease that poses a major threat to
vision in industrial countries. In glaucoma an
inner retinal component, the so called optic nerve
head component (ONHC), may be distinguished
from a more outer retinal component (RC) [7].
The ONHC is a nonlinear mfERG response
component whose propagation seems dependent
on the nerve ﬁber layer and which is attributed
mainly to the ganglion cell layer [7–12]. It
appears to be diminished in glaucoma [7, 13].
Recently a special slow mfERG stimulus se-
quence has been suggested to be sensitive in
OAG [14, 15]. With an increase in the stimulus
base interval to 53.3 ms or more, there is no
more overlap between the induced component
and the m-sequence response. Under these condi-
tions, oscillatory potentials become apparent in
the induced component [16, 17]. These mfOPs,
show a marked naso-temporal asymmetry [16,
17] which may be attributed to the misalignment
and partial cancellation of the RC with the
ONHC in the nasal retina and their relative
alignment and enhancement in the temporal ret-
ina [16]. Under these conditions the sensitivity to
detect normal tension OAG increases to about
85% [15].
The oscillatory potentials of the photopic
ERG receive a strong contribution from the in-
ner retinal layers [18]. Glycine, GABA and TTX
suppress the function of the inner retina and re-
sult in reduced or missing oscillatory potentials
of the photopic ERG [19]. In mfERG recordings
these substances also affect nonlinear contribu-
tions to the mfERG [12, 20].
In animal studies, mfERG waveforms similar
to those observed in glaucoma have been re-
ported following intravitreal injection of TTX. In
the slow mfERG TTX decreased the Ops and
largely eliminated their nasotemporal waveform
asymmetries [17]. TTX blocks some amacrine as
well as ganglion cells and interplexiform cells.
Therefore, the cellular origin of the mfERG
changes observed in glaucoma or following TTX
are still unclear and cannot be attributed exclu-
sively to ganglion cells [21]. As some amacrine
cells are dopaminergic, Parkinson’s disease would
be a potential model to gain further insight into
the cellular origin of these mfERG waveform
changes.
Parkinson’s disease is not only a motor sys-
tem disease. There is also a concurrent loss of
retinal dopamine [22]. This has resulted in a
spatial frequency dependent loss of sensitivity
for the pattern ERG (PERG) [23, 24] as well as
in abnormal pattern visual evoked potentials
(PVEP), presumably secondary to retinal chan-
ges [25, 26]. An increase in contrast sensitivity
threshold has also been reported in Parkinson’s
disease [23, 27]. It has been suggested that
dopamine has a push–pull effect in the primate
retina resulting in a tuned spatial response func-
tion [21]. The electrooculogram (EOG) has been
reported to show the earliest signs of retinal
dysfunction in the very early stages of Parkin-
son’s disease [28] and colour vision deﬁciencies
have been reported to progress during this dis-
ease [29].
Thus, in this pilot study an attempt was made
to assess the contribution of dopaminergic ama-
crine cells on the slow stimulation mfERG in pa-
tients with Parkinson’s disease following at least
12 h dopamine depletion.
Patients and methods
Patients with an early stage of Parkinson’s dis-
ease (clinical presentation as Hoehn and Yahr
stages I to II, that is with uni- or bilateral symp-
toms without alteration of balance) were re-
cruited from the Department of Neurology.
Following informed consent, eight patients vol-
unteered to participate in the testing of visual
function following a period of at least 12 h of
dopamine deficiency. (Dopamine intake was dis-
continued for >12 h independent of this study in
order to evaluate a patient’s response to a one
time dose of L-dopa.) Exclusion criteria were a
history of ocular surgery, ocular diseases, espe-
cially glaucoma or diabetic retinopathy as well as
high refractive errors +/) 6 dpt. A morphologic
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ophthalmic examination followed the testing of
visual function described below, to rule out oph-
thalmic disorders that may affect the results. The
patients’ right eye was examined, except in one pa-
tient where the right eye had a posterior capsular
fibrosis following cataract surgery. In this pa-
tient, the left eye was included in the study.
Patients underwent testing of EDTRS visual
acuity, testing of contrast sensitivity using the
Pelli Robson Chart as well as testing of colour
vision with the help of the saturated and desatu-
rated panel D15 test. Goldmann perimetry was
obtained to rule out visual field defects. A PERG
was obtained with a checkerboard check size of
60¢ as well as 90¢. Further electrophysiology
(Ganzfeld ERG, EOG and PVEP) was per-
formed according to ISCEV standard.
Following these examinations patients under-
went mfERG recordings as follows:
In all subjects mfERGs were recorded of one
eye, which in control subjects was chosen at random,
using VERISTM. MfERG signals were recorded
monocularly using a Burian–Allen bipolar contact
lens electrode. Pupils were dilated. The viewing
distance was adjusted according to the optimal
refraction used at a viewing distance of 40 cm to
ensure a constant image size [30].
During recording, the central 50 deg of the ret-
ina were stimulated by 103 hexagons where each
hexagon flickered according to a slow m-sequence
stimulation. Patients underwent two recordings
that lasted 7 min 17 s each.
For the first mfERG recording, each m-se-
quence step (M) with a luminance of either
100 cd/m2 or <1 cd/m2 was followed by 7 black
frames (B) with a luminance <1 cd/m2. This
eight frame stimulus sequence (MBBBBBBB)
reoccurred every 106.6 ms. The length of the
m-sequence was 212–1. The second mfERG
recording differed in that only three black frames
followed an m-sequence step (MBBB) resulting
in a stimulus base interval of 53.3 ms. The length
of the m-sequence was 213–1.
To enhance the signal-quality each recording
was split into 16 cycles of about 27.29 s. The raw
signals were filtered (10–300 Hz) and amplified
(gain=100 000). A sampling point was obtained
every 0.83 ms. An artifact elimination technique
[31] was applied once. The ﬁrst order response
component (KI) was analyzed. For each location
KI is calculated as the difference between the
mean local response to all the bright m-sequence
stimuli and the mean focal response to the black
m-sequence stimuli occurring in a stimulus cycle
and taking into account the entire stimulus base
interval.
Results
Mean age of the patients was 62.5 (SD 9.9)
years. All patients tested were in an early stage
of Parkinson’s disease (Schwab scale >80), that
is they could still cope with every day aspects of
life, taking twice as long as healthy people to
perform these tasks and being aware of this
handicap.
On the EDTRS visual acuity chart patients
could on average read 60 letters (SD 11). This
corresponds to an acuity equivalent of 20/32.
Contrast sensitivity as tested with the Pelli
Robson Chart was not impaired. On average pa-
tient could achieve Pelli Robson Scores of 1.56
(SD 0.2) which compared to 1.67 (SD 0.06) in a
healthy control group.
On colour vision testing four patients had sig-
nificant abnormalities with the desaturated panel
D15 colour plates, consisting of at least three
confusion lines along the tritan axis.
The electrooculogram was within the range of
normal with an Arden ratio of 2.0 (SD 0.6).
Amplitudes and latencies of the scotopic and
photopic Ganzfeld ERG were normal in Parkin-
son patients.
Due to a reduced signal-to-noise ratio, the
P-ERG could only be analyzed in four patients. In
a healthy control group, the N35-P50 amplitude
ratio of the 60¢ and the 90¢ check size was 1.06 lV
(SD 0.27). This compared well to Parkinson
patients with a mean ratio of 1.03 lV (SD 0.3).
P100 VEP latencies were normal (mean: 110
(SD 8.9 ms). The N75–P100 VEP amplitude was
slightly reduced by up to 3 lV below the range
of normal in three patients.
A multifocal ERG could be obtained in all
eight patients. However, only four patients had
an adequate signal-to-noise ratio permitting fur-
ther analysis of the data, one of whom was later
diagnosed with multi system atrophy (MSA).
These patients had been treated with L-Dopa
250–500 mg/day which they had discontinued at
least 12 h prior to examination.
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Figure 1 shows the areas of the response aver-
ages that were analyzed from the central 7.5 deg
and the four adjoining quadrants. These response
averages were chosen, as a naso-temporal asym-
metry of the mfOPs has previously been observed
[16, 17]. Figure 2 shows the corresponding
response averages. On average, the amplitude
from the ﬁrst negative trough (N1) to the ﬁrst po-
sitive peak (P1) was slightly, but not signiﬁcantly,
lower in the central (Parkinson patients’ mean:
32 nV/deg2, control mean: 46 nV/deg2)) and nasal
response averages of Parkinson patients. How-
ever, when the Parkinson patient’s responses (3
bottom traces) and the patient with MSA (dashed
line) were compared to four healthy volunteers
(top 4 traces) no signiﬁcant differences in wave-
form, amplitudes or latencies were observed. In
particular, the oscillatory potentials at a latency
of about 70–90 ms were present in all patients.
Figure 3 shows the same response averages
shown in Figure 2, but with a different ﬁlter set-
ting of 100–300 Hz. The waveforms were ﬁltered
ofﬂine at 100–300 Hz in order to facilitate analy-
sis of the oscillatory potentials. With this ﬁlter
setting, OPs resulting from the m-sequence step
stimulus can be visualized as well as those OPs
resulting from the induced component, that is the
stimulus in the sequence following the m-se-
quence step. Here, the most marked difference
was observed in the nasal response average of
the ﬁrst OP. In the upper nasal ﬁeld a mean
amplitude of 1.3 nV/deg2 in patients compared to
a mean amplitude of 1.93 nV/deg2 in the control
group (P: 0.08). In the lower nasal ﬁeld, the
mean amplitude of 0.84 nV/deg2 in patients com-
pared to a mean amplitude of 1.48 nV/deg2 in
the control group (P: 0.08). Again there was no
signiﬁcant difference between the patients and
healthy volunteers. OP-latencies also did not dif-
fer from normal. Enhancing the OPs by adding
the OPs of the m-sequence step to those of the
induced component failed to produce abnormal
responses in the Parkinson patients.
Increasing the stimulus base interval to
106.6 ms also did not reveal retinal dysfunction
in Parkinson patients other than a slight reduc-
Figure 1. The areas of the response averages that were ana-
lyzed from the central 7.5 deg and the four adjoining quad-
rants.
Figure 2. The responses resulting from the group averages shown in Figure 1 are depicted. For each response average, Parkinson
patient’s responses are shown in the three bottom traces, the patient with MSA is depicted by a dashed line, while for comparison,
the waveforms of four healthy volunteers are also shown (top 4 traces). Note, that there are no signiﬁcant differences in waveform.
In particular, mf-oscillatory potentials are present in all patients.
212
tion in the central amplitudes of the OPs in Par-
kinson patients. With this stimulus sequence, an
induced component was no longer apparent
(Figure 4). For the same recording length, this
stimulus sequence contains less signal than the
M3B sequence and therefore has a reduced sig-
nal-to-noise ratio.
Discussion
Our study shows that is possible to obtain
mfERG recordings with a good signal-to-noise
ratio in patients with moderate stages of Parkin-
son’s disease. However, even in these early stages
of disease, overlapping muscle artifacts resulted
Figure 3. The same response averages shown in Figure 2, but with a different ﬁlter setting of 100–300 Hz to facilitate analysis of
the oscillatory potentials. With this ﬁlter setting, OPs resulting from the M-sequence step stimulus are visualised between 20–50 ms,
as well as those OPs resulting from the induced component (70–90 ms).
Figure 4. The same response averages for the M7B Stimulus with a ﬁlter setting of 100–300 Hz to facilitate analysis of the oscilla-
tory potentials. With this stimulus sequence, an induced component is no longer apparent. For the same recording length, this
stimulus sequence contains less signal than the M3B sequence. Central amplitudes of the OPs appear slightly reduced in Parkinson
patients.
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in a bad signal-to-noise ratio preventing further
mfERG signal analysis in 50% of the patients.
While this pilot study included only a small
number of patients, we nevertheless found a con-
sistent presence of three mfOPs which is in con-
trast to our previous findings in NTG. Adjusting
for the number of tests, electrophysiologic exam-
inations showed no significant abnormalities in
Parkinson patients. These negative results do not
result from therapeutic dopamine substitution as
L-dopa, which has a short half life of 2–3 h, had
been discontinued at least 12 h prior to examina-
tion and these patients had been and were on no
other medication.
Lack of dopamine in these patients with mild
to moderate signs of Parkinson’s disease seems to
have little influence on the mfERG, and espe-
cially the mfOPs of the induced component un-
der the stimulus conditions applied. Thus,
dopaminergic amacrine cell dysfunction under
these conditions may only have a minor influence
on the mfERG recorded in moderate stages of
Parkinson’s disease. We cannot rule out, that dif-
ferences might have become apparent had we
been able to record more patients or more ad-
vanced stages of disease. In more advanced
stages of Parkinson’s disease an increased impair-
ment due to motor symptoms such as tremor can
be expected to render testing even more difficult.
Therefore, we feel that in order to further
study the influence of dopaminergic amacrine cells
on the mfERG, animal studies offer promising
alternatives: systemic application of 1-methyl,
4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) has
been shown to decrease retinal dopamine content
in primates [32]. Thus a possible animal model to
examine the effect of dopamine depletion on the
mfERG may be the application of MPDT. In-
deed, in the primate model, MPDT has been
shown to result in spatial frequency dependent
changes in the PERG and PVEP [33]. Intravitreal
application of this agent may allow for dose-effect
analysis with the advantage of not inducing sys-
temic motor symptoms such as tremor.
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